Merck is buying into a Cancer Research U.K. program that targets an enzyme key to the development of cancer and blood disease, wagering as much as $515 million on the effort.
It's not a new argument, but it's back on the table again now in a big way. Activist investor Artisan Partners is working to convince other investors to back splitting conglomerate Johnson & Johnson into three separate businesses.
Sanofi's animal health division, Merial, has been exploring ways to integrate new technology into their product offerings. They stepped up that effort on January 28, announcing a partnership with the Georgia Institute of Technology that's centered on using connected devices to advance animal health.
CRO giant Parexel has inked a new pact with the Optum Life Sciences unit of the nation's largest insurer, UnitedHealth Group, to help lower costs in postapproval studies.
Abbott has partnered with Chicago, IL-based Matter, a healthcare technology incubator, in its latest bid to access innovation. The diversified conglomerate, which markets nutrition, diagnostics, established pharmaceutical and medical device products, is under pressure to improve revenue growth and profitability in the wake of its 2013 split from the biopharma R&D-oriented AbbVie.
The University of Southern California Center for Body Computing has teamed with 8 partners to launch a Virtual Care Clinic. The idea with VCC is to create an integrated approach to the use of mobile apps, "virtual" doctors, artificial intelligence, data collection and analysis, as well as diagnostics and wearable sensors to create truly on-demand healthcare.
Minneapolis-based Minnetronix was founded in 1996 to offer engineering and manufacturing services to medical device companies. Now, it's raised its first equity capital since its inception with a $20 million investment from Altaris Capital Partners that gives the healthcare private equity firm a minority stake.
Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.
Using a "systems vaccinology" approach, researchers at Case Western Reserve University School of Medicine and Merck Research Laboratories have published findings that suggest a new way to predict and enhance vaccine effectiveness, in particular with hepatitis B vaccination.
Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $80 million. Now the Cambridge, MA, company has boosted its funding total to $92 million, extending its runway as it works through early-stage R&D.